Kalaris Therapeutics (NASDAQ:KLRS) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of Kalaris Therapeutics (NASDAQ:KLRS) from a hold rating to a sell rating in a research note issued to investors on Saturday.

Other analysts have also recently issued reports about the stock. Chardan Capital assumed coverage on shares of Kalaris Therapeutics in a report on Tuesday, December 23rd. They issued a “buy” rating and a $19.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Kalaris Therapeutics in a report on Monday, December 29th. Finally, Citigroup reissued an “outperform” rating on shares of Kalaris Therapeutics in a research report on Thursday, December 18th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Kalaris Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $14.00.

Kalaris Therapeutics Trading Up 1.8%

Kalaris Therapeutics stock opened at $10.00 on Friday. Kalaris Therapeutics has a 52 week low of $2.14 and a 52 week high of $12.90. The stock has a market cap of $187 million, a P/E ratio of -2.65 and a beta of -0.13. The stock has a 50 day moving average of $9.37 and a 200-day moving average of $7.03.

Insider Buying and Selling at Kalaris Therapeutics

In other news, Director Srinivas Akkaraju purchased 479,847 shares of the company’s stock in a transaction that occurred on Thursday, December 18th. The shares were acquired at an average cost of $10.42 per share, with a total value of $5,000,005.74. Following the transaction, the director owned 1,979,847 shares in the company, valued at approximately $20,630,005.74. The trade was a 31.99% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 74.99% of the company’s stock.

Hedge Funds Weigh In On Kalaris Therapeutics

A number of hedge funds have recently added to or reduced their stakes in KLRS. RTW Investments LP bought a new stake in Kalaris Therapeutics during the fourth quarter valued at $10,972,000. Paradigm Biocapital Advisors LP bought a new position in shares of Kalaris Therapeutics in the 4th quarter worth about $5,908,000. Alyeska Investment Group L.P. bought a new position in shares of Kalaris Therapeutics in the 4th quarter worth about $3,402,000. Ikarian Capital LLC acquired a new position in shares of Kalaris Therapeutics in the 4th quarter valued at about $3,038,000. Finally, Woodline Partners LP acquired a new position in shares of Kalaris Therapeutics in the 3rd quarter valued at about $1,394,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.